7月22日，Ionis Pharmaceuticals盘前下跌6.35%，报50.0美元/股，成交额7.72万美元。
消息面上，公司将于7月29日发布Q2财报，分析师对短期业绩持偏谨慎态度，看空比例升高，核心担忧在于合作里程碑的不确定性与费用刚性使本季度营收与利润率面临回落风险。此前7月9日，公司与阿斯利康联合开发的Eplontersen心脏转归III期试验未达主要终点，股价曾单日暴跌超20%。随后RBC将目标价从100美元下调至85美元，TD Cowen从108美元下调至94美元，市场情绪持续承压。尽管公司在Diranersen（阿尔茨海默病）及Zilganersen（亚历山大病）等管线取得积极进展，但短期内核心心血管管线受挫及财报季不确定性仍主导股价走势。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.